You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY20 is not expected to be complete until September, 2021.

  1. AAV2-ASPA-Based Metabolic Intervention for Alzheimer's Disease

    SBC: ASKLEPIOS BIOPHARMACEUTICAL, INC.            Topic: NIA

    Abstract We propose to initiate preclinical development of a gene therapeutic targeted to Alzheimer's Disease. The World Health Organization's and Alzheimer's Disease International's report on Dementia (2012) recognizes that the global burden of AlzheimerDisease is forecast to worsen significantly with prevalence predicted to double every 20 years. Interventions that could prov ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  2. Advanced Assessment to Accelerate Diagnostic Skill Acquisition

    SBC: Parallel Consulting, LLC            Topic: NIGMS

    DESCRIPTION (provided by applicant): Current approaches to medical education produce new physicians with insufficient clinical competency to practice effectively with limited supervision, which has serious implications for patient outcomes during hospitaloff hours. Up to 70% of patients admitted to a hospital are admitted on nights or weekends, when staffing is low and residents may be in charge o ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  3. A Genes-to-Molecules Platform for Expanding Natural Product Diversity

    SBC: Lassogen, Inc.            Topic: NCCIH

    Project Summary Natural products (NPs) and derivatives thereof provide a rich source of chemical matter for drug discovery and development. Over the past 30 years, NP-derived drugs have accounted for more than 35% of FDA approvals. Despite their demonstrated importance, development of new NPs has slowed over the past 15 years due to the lack of efficient methods for discovery, production, and opti ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  4. A Millimeter-wave Tunable Cavity for Ultra-sensitive Solids and Liquids DNP-NMR at Low Budget

    SBC: DOTY SCIENTIFIC, INC.            Topic: NIA

    ? DESCRIPTION (provided by applicant): NMR is probably the most powerful and widely used analytical technique for structure determination and function elucidation of molecules of all types, but it suffers from low sensitivity, particularly for insoluble biological macromolecules. Dynamic Nuclear Polarization (DNP) with Magic Angle Spinning (MAS) has recently demonstrated S/N gains exceeding t ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  5. A molecularly targeted pre- and post-exposure vaccine for anthrax

    SBC: VLP BIOTECH, INC.            Topic: NIAID

    DESCRIPTION provided by applicant We have shown that immunization of rabbits with multiple antigenic peptides MAPs displaying sequence from domain of protective antigen PA elicit antibodies specific for a linear determinant within the loop of PA that mediate potent neutralization of lethal toxin LeTx in vitro We have now shown in two separate large studies that antibodies aga ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  6. Amplification-free megabase target-enrichment for next-generation sequencing

    SBC: Mission Bio, Inc.            Topic: NHGRI

    DESCRIPTION (provided by applicant): Target enrichment for next-generation sequencing enables researchers to reduce the burden of sequence data analysis, obtain higher levels of statistical significance by examining more genomes and increase sequencing coverage depth. The goal of this STTR proposal is to develop and commercialize a novel technology capable of amplification-free megabase target seq ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  7. A Multivalent Lyme Disease Vaccine Targeting Tick-Host-Pathogen Interactions

    SBC: L2 Diagnostics, LLC            Topic: NIAID

    DESCRIPTION provided by applicant This proposal seeks to develop a novel vaccine against Lyme disease by targeting Ixodes scapularis proteins critical for Borrelia burgdorferi transmission from the tick to mammalian host Earlier work has identified four tick proteins Salp TRE tHRF and TSLPI that facilitate different steps of spirochete transmission and immunity against these protein ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  8. Analysis of new compounds to treat familial hypercholesterolemia

    SBC: GRUTHAN BIOSCIENCE LLC            Topic: NHLBI

    PROJECT SUMMARY The long-term goal of the current proposal is to generate a new class of small molecules to treat familial hypercholesterolemia. Familial hypercholesterolemia (FH) patients suffer from excessively high levels of Low Density Lipoprotein Cholesterol (LDL-C), which if left untreated results in death from severe cardiovascular disease. FH is caused primarily by mutations in the LDL rec ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  9. A Novel, Field-Deployable, Biomimetic Narcotics Detector for the Identification of Fentanyl and Other Synthetic Opioids

    SBC: SEACOAST SCIENCE, INC.            Topic: NIDA

    AbstractThe alarming scope of the rapidly growing opioid epidemic has commanded the nation’s attention. The White House’s Council of Economic Advisers estimates that in 2015, the economic cost of the opioid crisis was over $504.0 billion (2.8% of GDP); and it is only expected to continue rising. Today, 1 in 5 fatalities amongst young adults is opioid related; with half a million fatal overdose ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  10. A novel role for Reelin therapeutics in inflammatory bowel disease

    SBC: REELIN THERAPEUTICS, INC.            Topic: 300

    Abstract Factors that contribute to the onset of inflammatory bowel disease (IBD) remain incompletely understood. Although specific genetic factors may increase risk, most IBD cannot be readily explained based on genetics. Dysbiosis in intestinal microbiomes also has been implicated. Once IBD is established, chronic inflammation is a central hallmark and also a major target for therapy. Both forms ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government